Osteoarthritis

To compare the role of anti-depressants (Desipramine) and NSAID (Dexibuprofen) in monosodium iodo acetate (MIA) induced chronic knee osteoarthritis (OA) in rats. Twenty four male wistar rats were divided into 4 groups of 6 animals each. Group I to IV served as Vehicle control, OA control, Desipramine and Dexibuprofen treated groups respectively. Group I received I.A. Injection of 50µl of  0.9%normal saline, and Group II to IV received I.A. Injection of 50µl MIA, and the treatment of drugs started on the same day. The animals will be monitored for  osteoarthritis parameters and/or depression on pre-dose day (day 0) and on day 1, 3, 5, 7, 11  14, 18, 21 and 28 th day. The rise in knee inflammation is almost similar in all MIA treated groups (p

Osteoarthritis (OA) is a group of chronic, painful, disabling condition affecting synovial joints. OA is the most common among elderly people. Approximately 80% of population above 65 years of age suffers from OA and this value reaches near to 100% with increasing age. Currently available treatments of OA provide symptomatic relief or slow the progression of disease. The oral or parenteral administration of these drugs causes serious systemic side effects leading to even withdrawal of certain drugs from market. To overcome these problems, localized IA drug delivery presents a new hope. A number of drugs have been investigated for their local effect after IA administration. A number of novel drug delivery systems are available for their own merits and demerits. This review discusses the pathophysiology of OA and formulation consideration of IA injections along with details of current and novel drug formulation for OA treatments.